A vascular embolization treatment system based on thermosensitive nanogel embolic agent

Abstract

The present invention relates to the field of interventional therapy technology, and discloses a vascular embolization treatment system based on a thermosensitive nanogel embolic agent, comprising a thermosensitive nanogel embolic agent and a syringe, wherein the thermosensitive nanogel embolic agent is pre-filled in the syringe, and a heat insulating portion is provided on the outside of the syringe. The thermosensitive nanogel achieves long-term conformal embolization from small blood vessels to large blood vessels through temperature-induced sol-gel phase transition. The present invention provides a heat insulating portion on the outside of the syringe, which plays a good heat insulating role, avoids the situation where the thermosensitive nanogel embolic agent causes phase change due to ambient temperature and human body touch, provides convenience for the transportation and storage of the thermosensitive nanogel embolic agent, makes the thermosensitive nanogel embolic agent more stable during surgery, and improves the success rate of the surgery.

Description

Technical Field

[0001] The present invention relates to the technical field of interventional therapy, and in particular to a vascular embolization therapy system based on a thermosensitive nanogel embolic agent. Background Art

[0002] Interventional therapy is a technology that uses imaging diagnosis as a basis and medical imaging diagnostic equipment such as DSA, CT and MRI as a guide to diagnose and treat diseases. It has the characteristics of less trauma, accurate positioning, high efficacy, fewer complications, quick results and strong repeatability. In addition to medical treatment and surgical treatment, interventional therapy has become the third largest clinical treatment method.

[0003] Transcatheter arterial chemoembolization (TACE) is an interventional treatment method widely used in clinical practice, mainly used for the treatment of advanced tumors. This method can embolize the blood supply artery of the tumor, effectively blocking its blood supply, causing tumor ischemia and necrosis, but has little toxic side effects on tissue cells in other parts, and has obvious therapeutic effects.

[0004] Among them, thermosensitive nanogel embolic agent is a new generation of intelligent responsive vascular embolic material. Compared with traditional embolic materials such as iodized oil and microspheres, it can effectively solve the contradiction between fluidity and embolic properties, and can achieve conformal embolization from the extremities to large blood vessels.

[0005] Existing thermosensitive nanogel embolic agents are liquid at room temperature. They can penetrate deep into the peripheral blood vessels of tumors and fill each level of blood vessels in sequence. Under the induction of body temperature, they undergo a phase change and transform into a solid to achieve conformal embolization of the tumor vascular network.

[0006] Existing thermosensitive nanogel embolic agents are often packaged and injected with syringes. However, due to the special temperature-sensitivity characteristics of thermosensitive nanogel embolic agents, the ambient temperature during storage, transportation and intraoperative operation, as well as the operator's grip during use, may cause phase changes in the product, affecting the intraoperative operation and product performance of the product.

[0007] Currently, embolic products on the market mainly use borosilicate glass syringes and sterile plastic syringes as syringes. Among them, borosilicate glass has stable performance, is not easy to deform and age, and is the preferred packaging material for high-value injection products, but its thermal conductivity is 1.2-1.5W / m·K, which is higher than most non-metallic materials and is not conducive to heat insulation; the thermal conductivity of sterile plastic is lower than that of borosilicate glass, at 0.25-0.35W / m·K, but still higher than most solid insulation materials (the thermal conductivity of air is 0.025W / m·K, for reference). Both are difficult to meet the application requirements of storage, transportation and intraoperative operation of thermosensitive gel embolic preparations, and ultimately it is difficult to obtain a vascular embolization treatment product with stable performance thermosensitive nanogel. Summary of the invention

[0008] The purpose of the present invention is to provide a vascular embolization treatment system based on a thermosensitive nanogel embolic agent to solve the technical problems in the prior art.

[0009] In order to achieve the above objectives, the present invention provides a vascular embolization treatment system based on a thermosensitive nanogel embolic agent, comprising a syringe and a thermosensitive nanogel embolic agent, wherein the thermosensitive nanogel embolic agent is pre-filled in the syringe, and a heat insulating portion is provided on the outside of the syringe.

[0010] Preferably, the syringe comprises:

[0011] A syringe, wherein the syringe has a cavity, an injection head connected to the cavity is disposed at one end of the syringe, and a base is disposed at the other end;

[0012] A plunger, the plunger is disposed in the cavity and can move back and forth from one end of the syringe to the other end in the cavity, and the thermosensitive nanogel embolic agent is pre-filled in the cavity between the plunger and the injection head;

[0013] A push rod, one end of which is connected to a side of the plunger away from the injection head, and the other end of which penetrates and extends out of the other end of the syringe;

[0014] A push plate is arranged at the other end of the push rod.

[0015] Preferably, the heat insulating part comprises a heat insulating tube, which is sleeved on the outside of the syringe, and a vacuum interlayer is formed between the inner wall of the heat insulating tube and the outer wall of the syringe.

[0016] Preferably, the thickness of the vacuum interlayer is 1.5-3.0 mm, and the vacuum degree is 1-100 Pa.

[0017] Preferably, the heat insulating part further includes a heat insulating gasket arranged on the outside of the heat insulating cylinder.

[0018] Preferably, the syringe further comprises a sheath, and the sheath is sleeved on the injection head.

[0019] Preferably, the syringe also includes a limiting sleeve, which includes a push plate sleeve, a push rod sleeve and a base sleeve connected in sequence, and the push plate sleeve, the push rod sleeve and the base sleeve are all provided with openings on the same side, and the push plate sleeve, the push rod sleeve and the base sleeve are clamped between the base and the push plate through the opening to limit the movement of the push rod.

[0020] Preferably, the syringe further comprises a booster, and the booster is disposed on the base.

[0021] Preferably, the thermosensitive nanogel embolic agent comprises 0.1-10 wt % of thermosensitive gel, 20-70 wt % of contrast agent and 16.5-70 wt % of solvent.

[0022] Preferably, the thermosensitive gel is an N-isopropylacrylamide copolymer, and the N-isopropylacrylamide copolymer can be one of poly(N-isopropylacrylamide-co-acrylic acid), poly(N-isopropylacrylamide-co-butyl methacrylate), poly(N-isopropylacrylamide-co-hydroxyethyl acrylate), and poly(N-isopropylacrylamide-co-methacrylic acid).

[0023] The contrast agent is one of iopamidol, iohexol, ioversol and iodixanol;

[0024] The solvent is a 0.1-2.0 wt % sodium chloride aqueous solution.

[0025] The beneficial effects of the present invention are:

[0026] By setting a heat-insulating part on the outside of the syringe, a good heat-insulating effect is achieved, which prevents the ambient temperature and human touch from causing phase change of the thermosensitive nanogel embolic agent, provides convenience for the transportation and storage of the thermosensitive nanogel embolic agent, makes the thermosensitive nanogel embolic agent more stable during the operation, and improves the success rate of the operation.

[0027] Other features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:

[0029] Figure 1 A schematic diagram of the assembly structure of a syringe and a heat insulation part according to an embodiment of the present invention is shown;

[0030] Figure 2 A schematic diagram of the assembly structure of a syringe and a heat insulation part according to an embodiment of the present invention is shown (without an infinite sleeve);

[0031] Figure 3 A cross-sectional view of a syringe according to an embodiment of the present invention is shown;

[0032] Figure 4 A top view of a syringe according to an embodiment of the present invention is shown;

[0033] Figure 5 A schematic diagram of the limit sleeve structure of an embodiment of the present invention is shown.

[0034] Description of reference numerals:

[0035] 100 syringe, 101 syringe, 1011 injection head, 1012 base, 102 plunger, 103 push rod, 104 push plate, 105 sheath, 106 limit sleeve, 1061 push plate sleeve, 1062 push rod sleeve, 1063 base sleeve, 107 booster;

[0036] 200 insulation part, 201 insulation tube, 2011 vacuum interlayer, 202 insulation gasket. DETAILED DESCRIPTION

[0037] The specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings. It should be understood that the specific implementation described here is only used to illustrate and explain the present invention, and is not used to limit the present invention.

[0038] Example 1

[0039] This embodiment provides a thermosensitive nanogel embolic agent, which contains a thermosensitive gel and a water-soluble contrast agent. The thermosensitive gel is a liquid at room temperature, can penetrate into the peripheral blood vessels of the tumor and complete the filling of each level of blood vessels in sequence, and undergoes a phase change to solid under the induction of body temperature, which can achieve conformal embolization of the tumor vascular network. The water-soluble contrast agent can be clearly imaged by DSA during TACE surgery. Therefore, the thermosensitive nanogel embolic agent of the present invention can replace the functions of liquid embolic agents, solid embolic agents, and contrast agents, and simplify the surgical process.

[0040] Preparation of thermosensitive nanogel embolic agent: 2.0 g of poly (N-isopropylacrylamide-co-acrylic acid) and 46.5 g of iohexol were dissolved in 51.5 g of 0.5 wt % sodium chloride aqueous solution to obtain a thermosensitive nanogel embolic agent.

[0041] Example 2

[0042] Preparation of thermosensitive nanogel embolic agent: 0.1 g of poly (N-isopropylacrylamide-co-butyl methacrylate) and 51.5 g of iopamidol were dissolved in 48.4 g of 0.1 wt % sodium chloride aqueous solution to obtain a thermosensitive nanogel embolic agent.

[0043] Example 3

[0044] Preparation of thermosensitive nanogel embolic agent: 3.5 g of poly (N-isopropylacrylamide-co-hydroxyethyl acrylate) and 70 g of ioversel were dissolved in 16.5 g of 2.0 wt % sodium chloride aqueous solution to obtain a thermosensitive nanogel embolic agent.

[0045] Example 4

[0046] Preparation of thermosensitive nanogel embolic agent: 10 g of poly (N-isopropylacrylamide-co-methacrylic acid) and 20 g of iodixanol were dissolved in 70 g of 0.1 wt % sodium chloride aqueous solution to obtain a thermosensitive nanogel embolic agent.

[0047] Example 5

[0048] Please refer to Figure 1-Figure 5 This embodiment provides a vascular embolization treatment system based on a thermosensitive nanogel embolic agent, including a syringe 100 and the thermosensitive nanogel embolic agent prepared in Example 1. The thermosensitive nanogel embolic agent is pre-filled in the syringe 100, and an insulating portion 200 is provided on the outside of the syringe 100.

[0049] When used specifically, the thermosensitive nanogel embolic agent can be injected into the designated position through the syringe 100, and the process of transferring the thermosensitive nanogel embolic agent from the packaging container to the syringe 100 is omitted during use, which has the advantages of convenient use, prevention of pollution, reduction of drug waste, and accurate dosing. In addition, a heat insulation part 200 is provided, which can play a good heat insulation role, avoid the situation where the thermosensitive nanogel embolic agent causes phase change due to ambient temperature and human body touch, and provide convenience for the transportation and storage of the thermosensitive nanogel embolic agent, making the thermosensitive nanogel embolic agent more stable during surgery, and improving the success rate of surgery.

[0050] In this embodiment, please refer to Figure 1-Figure 3 The syringe 100 includes a syringe 101, a plunger 102, a push rod 103, a push plate 104, a sheath 105, a stopper 106 and a booster 107. Specifically, the push rod 104 is made of polypropylene, polyethylene or polystyrene. The plunger 102 is made of halogenated butyl rubber, the sheath 105 is made of butyl rubber or polyisoprene rubber, and the syringe 101 is made of one of medium borosilicate glass, cycloolefin polymer (COP) or cycloolefin copolymer (COC). In this embodiment, the material of the syringe 101 is medium borosilicate glass.

[0051] The syringe 101 has a cavity, one end of which is provided with an injection head 1011 connected to the cavity, and the other end is provided with a base 1012. The plunger 102 is arranged in the cavity and can move back and forth from one end to the other end of the syringe in the cavity. The thermosensitive nanogel embolic agent is pre-filled in the cavity between the plunger 102 and the injection head 1011. One end of the push rod 103 is connected to the side of the plunger 102 away from the injection head 1011, and the other end of the push rod 103 penetrates and extends out of the other end of the syringe 101. The push plate 104 is arranged at the other end of the push rod 103. The injection head 1011 and the base 1012 are integrally formed with the syringe 101, and the material is the same as that of the syringe 101. When used specifically, the medical staff can press the push plate 104 to push the push rod 103, and the push rod 103 drives the plunger 102 to move downward, thereby squeezing out the thermosensitive nanogel embolic agent to complete the injection action.

[0052] In this embodiment, the syringe 101 is a hollow cylinder, and the base 1012 is a circular plate, and the two are coaxially arranged.

[0053] In this embodiment, the sheath 105 is sleeved on the injection head 1011. Specifically, the sheath 105 is threadedly connected to the injection head 1011 to prevent the temperature-sensitive nanogel embolic agent from being contaminated.

[0054] Please refer to Figure 1 , Figure 4 and Figure 5 The limiting sleeve 106 includes a push plate sleeve 1061, a push rod sleeve 1062 and a base sleeve 1063 connected in sequence. The push plate sleeve 1061, the push rod sleeve 1062 and the base sleeve 1063 are all provided with an opening on the same side. The push plate sleeve 1061, the push rod sleeve 1062 and the base sleeve 1063 are clamped between the base 1012 and the push plate 104 through the opening to limit the movement of the push rod 103. In this embodiment, the push plate sleeve 1061, the push rod sleeve 1062 and the base sleeve 1063 are integrally formed, and the push plate sleeve 1061, the push rod sleeve 1062 and the base sleeve 1063 have a certain elasticity. The openings of the push plate sleeve 1061 and the push rod sleeve 1062 are slightly larger than the diameters of the push plate 104 and the push rod 103, and the opening of the base sleeve 1063 is so large that it can be sleeved on the base 1012. During installation, the opening can be aligned with the installation position of the syringe 100 and then pressed hard. Since the push plate sleeve 1061, the push rod sleeve 1062 and the base sleeve 1063 have a certain elasticity, after being subjected to force, the push plate sleeve 1061, the push rod sleeve 1062 and the base sleeve 1063 are inserted into the push plate 104, the push rod 103 and the base 1012, thereby completing the installation of the limit sleeve 106. At this time, the push rod 103 cannot move up and down, avoiding accidental displacement of the push rod 103 due to force during transportation and storage, thereby causing waste of the thermosensitive nanogel embolic agent.

[0055] Preferably, the booster 107 is disposed on the base 1012 , and the booster 107 can increase the hand-held area and facilitate operation by medical personnel.

[0056] Preferably, the heat-insulating portion 200 includes a heat-insulating tube 201, which is sleeved on the outside of the syringe 101. The material of the heat-insulating tube 201 is the same as that of the syringe 101, which is one of medium borosilicate glass, cycloolefin polymer (COP) or cycloolefin copolymer (COC). In this embodiment, medium borosilicate glass is preferably used. A vacuum interlayer 2011 is formed between the inner wall of the heat-insulating tube 201 and the outer wall of the syringe 101. The vacuum interlayer 2011 can play a good role in heat insulation, avoiding the phase change of the thermosensitive nanogel embolic agent caused by ambient temperature and human body touch. The thickness of the vacuum interlayer 2011 is 2.0 mm, and the vacuum degree is 1 Pa. The heat-insulating tube 201 and the syringe 101 are integrally formed, which is more convenient to process.

[0057] The heat insulating part 200 further includes a heat insulating gasket 202 disposed outside the heat insulating tube 201. The heat insulating gasket 202 is made of a resin or plastic with a low thermal conductivity, preferably polyurethane, which acts as a heat insulator when held, further preventing the temperature sensitive gel from changing phase due to the temperature rise caused by holding.

[0058] When in use, the sheath 105 is removed, and the medical staff holds the thermal insulation gasket 202 and pushes the push rod 103 to move axially along the cavity toward the injection head 1011. The plunger 102 pushes the pre-filled temperature-sensitive nanogel embolic agent in the cavity out of the syringe 100. Due to the provision of the thermal insulation gasket 202 and the thermal insulation cylinder 201, the temperature-sensitive nanogel embolic agent always remains in a liquid state during the whole process.

[0059] In summary, the vascular embolization treatment system based on the thermosensitive nanogel embolic agent of this embodiment can play a good heat-insulating role by setting the heat-insulating part 200 on the outside of the syringe 100, avoiding the phase change of the thermosensitive nanogel embolic agent caused by the ambient temperature and human touch, and providing convenience for the transportation and storage of the thermosensitive nanogel embolic agent, making the thermosensitive nanogel embolic agent more stable during the operation, thereby improving the success rate of the operation.

[0060] Embodiment 6-7

[0061] Except for the difference in the materials of the syringe 101 and the heat-insulating tube 201 (COP and COC respectively), the rest is the same as in Example 1. The specific parameters are listed in Table 1.

[0062] Embodiment 8-11

[0063] Except for the difference in vacuum degree and thickness parameters of the vacuum interlayer 2011, other parameters are the same as those in Example 1. The specific parameters are listed in Table 1.

[0064] Comparative Example 1

[0065] The thickness of the vacuum interlayer 2011 is 1.0 mm, and the rest is the same as in Example 1.

[0066] Comparative Example 2

[0067] The syringe 100 is not provided with a heat insulating gasket 202 , and the rest is the same as in the first embodiment.

[0068] Comparative Example 3

[0069] The syringe 100 is not provided with a vacuum interlayer 2011, and the syringe barrel 101 and the heat-insulating barrel 201 are made of a single layer of medium-borosilicate glass. The rest is the same as in Example 1.

[0070] Comparative Example 4

[0071] The syringe 100 is not provided with a vacuum interlayer 2011, the syringe barrel 101 and the insulation barrel 201 are both made of a single layer of medium borosilicate glass, and no insulation gasket 202 is provided, and the rest is the same as in Example 1.

[0072] Comparative Example 5

[0073] The syringe 100 is not provided with a vacuum interlayer 2011, the syringe barrel 101 and the heat-insulating barrel 201 are both made of a single layer of COP, and no heat-insulating gasket 202 is provided, and the rest is the same as in Example 1.

[0074] Comparative Example 6

[0075] The syringe 101 is not provided with a vacuum interlayer 2011, the syringe barrel 101 and the heat-insulating barrel 201 are both made of a single layer of COC, and no heat-insulating gasket 202 is provided, and the rest is the same as in Example 1.

[0076] Test Example 1

[0077] The vascular embolization treatment system based on the thermosensitive nanogel embolic agent provided in Examples 1-7 and Comparative Examples 1-6 was placed in a constant temperature incubator at 35±0.1°C, and the time when the thermosensitive nanogel embolic agent undergoes phase change was recorded (observed throughout the process before 30 minutes and observed every 5 minutes after 30 minutes). The results are shown in Table 1.

[0078] Test Example 2

[0079] The vascular embolization treatment system based on the thermosensitive nanogel embolic agent provided in Examples 5-11 and Comparative Examples 1-6 was placed on an electric heating plate (the package with the thermal insulation gasket 202 kept the thermal insulation gasket 202 in contact with the heating plate) at a room temperature of 25±1°C, and the temperature of the heating plate was 37±1.0°C, simulating a human holding operation. The time when the thermosensitive nanogel embolic agent undergoes phase change was recorded (observed throughout the process before 30 minutes, observed every 10 minutes after 30 minutes, and the test time did not exceed 240 minutes), and the results are shown in Table 1.

[0080] Table 1 Investigation of thermal insulation performance of different packaging materials

[0081] Sample source Syringe / insulation tube material Interlayer (vacuum degree / thickness) Gasket Test 1 Test 2 Example 5 Medium borosilicate glass 1Pa / 2.0mm have 80min >240min Example 6 COP 1Pa / 2.0mm have 100min >240min Example 7 COC 1Pa / 2.0mm have 120min >240min Example 8 Medium borosilicate glass 10Pa / 3.0mm have 75min >240min Example 9 Medium borosilicate glass 100Pa / 3.0mm have 60min >240min Example 10 Medium borosilicate glass 1Pa / 1.5mm have 65min >240min Embodiment 11 Medium borosilicate glass 1Pa / 2.5mm have 125min >240min Comparative Example 1 Medium borosilicate glass 1bar / 1.0mm have 21min >240min Comparative Example 2 Medium borosilicate glass 1Pa / 2.0mm none 75min 40min Comparative Example 3 Medium borosilicate glass No interlayer have <1min 160min Comparative Example 4 Medium borosilicate glass No interlayer none <1min 2min Comparative Example 5 COP No interlayer none 1min 4min Comparative Example 6 COC No interlayer none 1min 5min

[0082] As shown in Table 1, the vacuum interlayer 2011 can significantly improve the tolerance of the thermosensitive nanogel embolic agent to environmental overtemperature, and the thermal insulation gasket 202 can eliminate the phase change risk caused by human holding (except for comparative example 3 without the vacuum interlayer 2011 design, no phase change occurred when the simulated holding exceeded 240 minutes).

[0083] The preferred embodiments of the present invention are described in detail above in conjunction with the accompanying drawings. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, and these simple modifications all belong to the protection scope of the present invention. It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

[0084] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.

Claims

1. A vascular embolization treatment system based on a thermosensitive nanogel embolic agent, characterized in that: It comprises a syringe (100) and a thermosensitive nanogel embolic agent, wherein the thermosensitive nanogel embolic agent is pre-filled in the syringe (100), and a heat insulating portion (200) is arranged on the outside of the syringe (100).

2. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 1, characterized in that: The syringe (100) comprises: A syringe (101), wherein the syringe (101) has a cavity, one end of which is provided with an injection head (1011) communicating with the cavity, and the other end of which is provided with a base (1012); A plunger (102), the plunger (102) being disposed in the cavity and being movable back and forth from one end of the syringe to the other end in the cavity, the thermosensitive nanogel embolic agent being pre-filled in the cavity between the plunger (102) and the injection head (1011); A push rod (103), one end of which is connected to a side of the plunger (102) away from the injection head (1011), and the other end of which penetrates and extends out of the other end of the syringe (101); A push plate (104), wherein the push plate (104) is arranged at the other end of the push rod (103).

3. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 2, characterized in that: The heat insulating part (200) comprises a heat insulating tube (201), wherein the heat insulating tube (201) is sleeved on the outside of the syringe (101), and a vacuum interlayer (2011) is formed between the inner wall of the heat insulating tube (201) and the outer wall of the syringe (101).

4. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 3, characterized in that: The thickness of the vacuum interlayer (2011) is 1.5-3.0 mm, and the vacuum degree is 1-100 Pa.

5. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 3, characterized in that: The heat insulating portion (200) further comprises a heat insulating gasket (202) arranged outside the heat insulating cylinder (201).

6. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 2, characterized in that: The syringe (100) further comprises a sheath (105), wherein the sheath (105) is sleeved on the injection head (1011).

7. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 6, characterized in that: The syringe (100) further comprises a limiting sleeve (106), wherein the limiting sleeve (106) comprises a push plate sleeve (1061), a push rod sleeve (1062) and a base sleeve (1063) which are connected in sequence, and an opening is provided on the same side of the push plate sleeve (1061), the push rod sleeve (1062) and the base sleeve (1063), and the push plate sleeve (1061), the push rod sleeve (1062) and the base sleeve (1063) are clamped between the base (1012) and the push plate (104) through the opening to limit the movement of the push rod (103).

8. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 7, characterized in that: The syringe (100) further comprises a booster (107), wherein the booster (107) is disposed on the base (1012).

9. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to any one of claims 1 to 8, characterized in that: The thermosensitive nanogel embolic agent comprises 0.1-10 wt % of thermosensitive gel, 20-70 wt % of contrast agent and 16.5-70 wt % of solvent.

10. The vascular embolization treatment system based on the thermosensitive nanogel embolic agent according to claim 9, characterized in that: The thermosensitive gel is an N-isopropylacrylamide copolymer; The contrast agent is one of iopamidol, iohexol, ioversol and iodixanol; The solvent is a 0.1-2.0 wt % sodium chloride aqueous solution.

Images